Background: Anaplastic lymphoma kinase (ALK) fusions need to be accurately and efficiently detected for ALK inhibitor therapy. Fluorescence in situ hybridization (FISH) remains the reference test. Although increasing data are supporting that ALK immunohistochemistry (IHC) is highly concordant with FISH, IHC screening needed to be clinically and prospectively validated.
introduction Patient selection is a key factor for molecular-targeted therapy. A molecular-targeted drug does not work appropriately, or rather may be harmful, if used for the patients without its molecular target. Good molecular targets are those that are not widely expressed in normal tissues and on which cancers are heavily 'addicted' for growth and survival. Accordingly, anaplastic lymphoma kinase (ALK) is one of the most desirable molecular targets. Only 4 years after the discovery of an oncogenic fusion, EML4-ALK [1] , an ALK inhibitor, crizotinib, with an overall response rate (ORR) of 57%, was approved for therapy of ALK-positive lung cancer (ALK+ LC) [2] .
ALK fusions are found in only 4%-6% of lung adenocarcinomas [3, 4] . There are three major conventional diagnostics for ALK fusions: fluorescence in situ hybridization (FISH), RT-PCR, and immunohistochemistry (IHC). As of September 2015, the Vysis ALK Break Apart FISH Probe Kit (Vysis FISH) (Abbott) is the only approved companion diagnostic test for prescribing crizotinib in Japan. In the United States, a high-sensitive IHC, VENTANA ALK (D5F3) CDx Assay, was also approved, resulting in two companion diagnostics. In Europe, crizotinib is approved for patients with ALK+ LC, but the type of test used for ALK fusion detection is not specified.
Alectinib is a second-generation ALK inhibitor with potent in vitro activity against both wild-type and mutated ALK, including mutations that confer resistance to crizotinib [5] . The results of the phase I/II study, AF-001JP, showed that alectinib is highly effective against ALK+ LC [ORR, 93.5%; 95% confidence interval (CI) 82.1-98.6] and well tolerated [6] . Two ALK inhibitors, crizotinib and alectinib, are currently approved in Japan. A highly sensitive immunohistochemical companion diagnostic, Histofine ALK iAEP kit (Nichirei Bioscience), which is based on the intercalated antibody-enhanced polymer (iAEP) method [4] Figure 1 . Demographics of the patients examined for ALK fusions. One patient with iScore 3 had negative results for RT-PCR and the FISH analysis failed. However, the patient had positive FISH results outside this trial and was enrolled in another trial for crizotinib. In this study, this patient was assigned 'not evaluable' for the presence of ALK fusions (*), because the presence was confirmed outside the trial. In the trial, 436 patients were examined for ALK fusions between 10 September 2010, and 18 April 2012. The patients were screened with IHC (n = 384), multiplex RT-PCR (n = 68), or both (n = 16). Formalin-fixed paraffin-embedded (FFPE) specimens were used for IHC screening with the ALK Detection Kit (now renamed as Histofine ALK iAEP kit), and unfixed specimens ( pleural effusion, bronchoalveolar lavage, sputum, or frozen tumor tissues) were used for multiplex RT-PCR screening [3] . In the samples for RT-PCR, the presence of cancer cells was not always examined by morphology.
ALK IHC results were classified into four categories according to the rate of positively stained tumor cells: positive ( positive tumor cells >80%), probably positive (80%≥ positive tumor cells >50%), probably negative (50%≥ positive tumor cells >0%), and negative (0%). After patient selection for the trial, these four categories were renamed as iScore 3, 2, 1, and 0, respectively [7] , and therefore, we use the term 'iScore' hereafter. For patients with iScore >0, FISH was subsequently performed for confirmation using in-house probes, which were confirmed to be sufficiently concordant with Vysis FISH. An experienced board-certified pathologist (KT) judged IHC and FISH results. The intensity of IHC staining was evaluated with Ariol (Leica Biosystems). Multiplex RT-PCR was performed and judged by a commercial clinical laboratory (SRL, Tokyo). Since the presence of cancer cells in the samples for RT-PCR was not always examined, ALK fusion negativity could not be ascertained in 49 patients. Among the 384 patients screened with IHC, 9 patients could not be scored because no cancer cells were observed in their specimens. FISH was initially performed for the 129 patients with iScore >0, and after the inclusion period, for the 52 patients who had iScore 0 and provided consent for the additional FISH study. Since 7 patients failed in FISH, results of both IHC and FISH were evaluable in 174 patients. When iScore 3 was defined as IHC-positive and others as IHC-negative, sensitivity, specificity, positive predictive value, and negative predictive value of IHC compared with those of FISH were 100% (122/122), 98.1% (51/52), 99.2% (122/123), and 100% (51/51), respectively. The concordance rate was 99.4% (173/174).
The patient who showed iScore 3 and a negative FISH result had a large-cell neuroendocrine carcinoma. Although the proportion of positively stained cancer cells was slightly >80%, IHC staining intensity of each cancer cell was highly variable (a checker-board pattern) (supplementary Figure S1 , available at Annals of Oncology online). In ALK fusion gene-positive samples stained with ALK iAEP IHC, almost all cancer cells stain positive, while heterogeneous staining patterns including a checker-board pattern indicated the expression of wild-type ALK [7, 8] . Therefore, after the trial, the original scoring criteria were slightly amended to exclude cases with a checkerboard pattern from iScore 3 to iScore 2. The current version of iScore is given in Table 1 .
RT-PCR was performed in 68 patients including 16 patients who underwent both IHC and RT-PCR screening. Two patients who had iScore 3 but failed in FISH turned positive in RT-PCR. One patient showed a discordant result (IHC-positive, RT-PCRnegative, and failed in FISH). Outside the trial, however, the patient had a positive FISH result and was enrolled in another trial for crizotinib. As of 31 October 2014, all 46 patients in phase II showed at least 30% reduction in tumor size, and 28 were on treatment with alectinib [9] . Nine and 34 patients achieved complete response (CR) and partial response (PR), respectively. One patient remained in stable disease (SD), and 2 had an unknown response (UN) due to early withdrawal. The ORR was 93.5%. The median follow-up duration reached 30 months (range: 1-36), but PFS events were confirmed in only 15 patients (32.6%; 12 PD and 3 deaths) ( Figure 2C) . Therefore, the median PFS will be more than 29 months. ALK IHC specimens of the 41 patients were examined for staining intensity. The maximum staining intensity was not correlated with the rate of tumor size reduction ( Figure 2D ).
iScore 3 cases with atypical FISH patterns
In 122 patients who had iScore 3 and were judged positive for FISH, two showed an atypical FISH pattern, the isolated 5 0 -side signal pattern. We performed FISH again with Vysis FISH, and obtained the same results ( Figure 3C -E and J-L). This pattern is currently defined as negative in the criteria for Vysis FISH. However, we judged these cases positive for ALK fusion because (i) all the cancer cells clearly showed ALK expression by IHC (iScore 3; Figure 3B and I); (ii) both cases showed a mucinous cribriform pattern on histopathological analysis, which is the characteristic of ALK+ LC [10] ( Figure 3A and H); and (iii) the ALK locus was indeed rearranged although the observed FISH pattern was atypical. One patient (IHCF8007) was enrolled in phase II and showed PR with a maximum tumor reduction of 48.1% ( Figure 3F and G). The other patient (IHCF12028) was not enrolled for alectinib therapy but was treated with crizotinib outside the trial, and showed good response ( Figure 3M and N) . After the therapy, we examined these cases for ALK fusion partners by 5 0 -RACE optimized for FFPE specimens [11] . In IHCF8007, the variant 3 of the EML4-ALK transcript (E6;E20) was identified. We failed to identify the fusion partner in IHCF12028, probably due to severe mRNA degeneration.
discussion
Among the 126 patients with iScore 3, 124 were confirmed positive for ALK fusions in the trial, and 1 was outside of the trial. All the 41 patients who continued into phase II showed at least 30% tumor reduction with an ORR of 92.7%. This rate indicated that ALK iAEP IHC judged by iScore has sufficient specificity. The trial might have some limitations with respect to analyzing sensitivity. FISH was initially performed only for patients with >iScore 0 and was done retrospectively only for 52 additional patients with iScore 0. In addition, for the analysis of retrospectively performed FISH, the knowledge of IHC results might introduce a potential bias. However, the results of two other studies compensate for these limitations. In these two studies, in which the concordance of IHC and FISH was examined, ALK iAEP (ALK Detection Kit results judged by iScore) and Vysis FISH were blindly performed without any knowledge of the other test results. One study was previously reported [7] , and the data of the other study have been submitted to the Ministry of Health, Labour, and Welfare for approval of the ALK iAEP kit. Both studies showed high concordance rates. As a total of the three studies including the present one, the sensitivity, specificity, and positive and negative predictive values of IHC to FISH were 99.5% (182/183), 99.9% (594/595), 99.5% (182/183), and 99.9% (594/595), respectively ( Table 2) .
We encountered two cases of iScore 3 that showed an atypical FISH pattern, that is, an isolated 5 0 -side signal pattern. Given that an EML4-ALK transcript was identified in one of these cases and that both cases responded to ALK inhibitor therapy, the ALK kinase domain was preserved in the rearranged allele, although the 3 0 -side FISH signal was not observed. The length of the ALK kinase domain is only 30 kb, that is, 5-20 times shorter than typical FISH probes; thus, most of the 3 0 -side ALK FISH probe covers the downstream region outside ALK ( Figure 4A-C) . In cases with an isolated 5 0 -side signal pattern, the ALK downstream region is highly likely to be largely deleted, and the remaining region including the ALK kinase domain, ∼30 kb, is too short to be clearly observed with FISH on FFPE specimens. This results in an isolated 5 0 -side signal pattern ( Figure 4D ). There are several reports of cases showing an isolated 5 0 -side signal pattern accompanied by IHC positivity [12, 13] or negativity [14] . The latter IHC-negative cases harbored KRAS mutations indicating that ALK was not functionally rearranged [14] , because KRAS mutations are usually mutually exclusive to ALK fusions. One of the IHC-positive patients was treated with, and responded to, an ALK inhibitor [13] , like our two patients. In addition, some patients did not show isolated signals, but showed only the merged signal(s), known as 'wild-type pattern', although their IHC and RT-PCR results were positive [15] . In such cases, ALK fusion formation may be accompanied by some very rare events, for example, simultaneous deletions of 5 0 and downstream regions, a large deletion between ALK and EML4, and small insertions ( Figure 4E-G) . Among the patients with atypical FISH patterns, which are regarded as negative in the current criteria, some had positive results for IHC, RT-PCR, or both and responded to ALK inhibitor therapy [13, 16] . Therefore, when atypical FISH patterns are accompanied by positivity in other methods, most often IHC, it is reasonable to recognize such patterns as functional ALK rearrangements. The molecular target of ALK inhibitors is ALK protein, not the ALK gene.
After the trial, alectinib was approved on 4 July 2014 and became the second approved ALK inhibitor in Japan. Meanwhile, Histofine ALK iAEP kit (ALK iAEP) was approved as a companion diagnostic for alectinib, but not for crizotinib. Alectinib and ALK iAEP were listed on the National Health Insurance reimbursement list on 2 September 2014. Currently, in Japan, Vysis FISH is the only companion diagnostic for crizotinib (approved in 2012), and can also be used for alectinib because it was confirmed to be equivalent to the in-house ALK FISH probes used in the present trial. ALK iAEP, Vysis FISH, and the in-house probes were proven equivalent to each other for the detection of (Table 2) . However, according to the package insert of alectinib, both Vysis FISH and ALK iAEP have to be performed before patients can start alectinib therapy, although FISH was performed in the trial only for confirmation of IHC screening results and the two tests were almost concordant with each other. In contrast, Vysis FISH results alone are sufficient for initiating crizotinib therapy. On 9 September 2014, the Japan Lung Cancer Society (JLCS) made a statement concerning such a complicated situation: '… The concept of companion diagnostics is based on the principle that the same diagnostics used in the trial should also be used in the practice to reproduce the efficacy and safety of the drug proven in the trial … However, it is self-evident that what should be companioned with a molecular-targeted drug is a target, not a diagnostic. If the regulatory agency strictly adheres to the principle and instructs physicians to comply with the regulations, then scientifically illogical situations might occur. For example, patients might not be reimbursed for ALK iAEP if it is used for crizotinib, or the patients diagnosed with Vysis FISH and treated with crizotinib might have to further undergo ALK iAEP screening to receive second-line alectinib therapy …' (authors' translation). Crizotinib and alectinib share the same targeted molecule and disease, but their companion diagnostic test requirements are different. This situation is leading to concerns in clinical practice in Japan, such as the following: there will be several molecular-targeted drugs to the same molecular target X; there will be several diagnostics for the same molecular target X; however, each drug to X will be companioned only with its specific diagnostic for X, and thus patients will have to take another diagnostic for X when they take another drug to X. Such a 'tragicomedy' should be scientifically considered and avoided for the benefit of patients. A more scientifically downto-earth principle is recommended; when the response of a drug is proved to be predicted reliably with a biomarker and the biomarker is proved to be detected reliably with a diagnostic, the diagnostic should be companioned with the drug even if it is not used in the trial.
In conclusion, our study showed (i) that when ALK IHC is sufficiently sensitive and appropriately interpreted, it can be a stand-alone diagnostic for ALK inhibitor therapies; (ii) that when atypical FISH patterns are accompanied by IHC positivity, the patients should be considered as candidates for ALK inhibitor therapies; and (ii) that the expression level of ALK fusion is not related to the level of response to ALK inhibitors and is thus not required at least for patient selection. With the diversification of diagnostics for molecular targets, the interpretation of and the regulation policy for companion diagnostics are expected to evolve further.
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